The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the supplemental new drug ...

Cases of several dangerous bacterial infections and viruses have been growing around the U.S. CBS News medical contributor Dr ...

The FDA has denied Astellas’ attempt to bolster the label for its vision loss treatment Izervay with additional two-year data ...

Investing.com - Shares of biopharmaceutical firm Apellis Pharmaceuticals Inc (NASDAQ: APLS) surged 16.44% to $31 on Tuesday ...

The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Jefferies analyst Akash Tewari maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

Astellas Pharma (ALPMY) announced the Food and Drug Administration issued a Complete Response Letter regarding the supplemental new drug ...